AVTR
Avantor, Inc.
NYSE · Healthcare · Medical - Instruments & Supplies · US
$16.68
−0.06%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 6.6B | 6.6B | 6.8B | 7.0B | 7.5B |
| Cost of Revenue | 4.5B | 4.4B | 4.5B | 4.6B | 4.9B |
| Gross Profit | 2.1B | 2.1B | 2.3B | 2.4B | 2.6B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 1.2B | 1.6B | 1.6B | 1.5B | 1.5B |
| General & Admin Expense | 395.3M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 390.8M | 790.1M | (446.6M) | 160.8M | — |
| Total Operating Expenses | 1.6B | 2.4B | 1.2B | 1.7B | 1.5B |
| Cost and Expenses | 6.1B | 6.8B | 5.7B | 6.3B | 6.4B |
| Operating Income (EBIT) | 502.7M | (246.2M) | 1.1B | 696.4M | 1.1B |
| Non-Operating | |||||
| Interest Income | 10.5M | — | — | — | — |
| Interest Expense | 174.6M | 169.8M | 218.8M | 284.8M | 265.8M |
| Net Interest Income | (164.1M) | (169.8M) | (218.8M) | (284.8M) | (265.8M) |
| Other Non-Op Income/Expense | (187.2M) | (195.1M) | (230.9M) | (285.9M) | (279.1M) |
| Non-Operating Income (excl Interest) | 12.6M | 25.3M | 12.1M | 1.1M | 13.3M |
| EBT (Pre-Tax Income) | 315.5M | (441.3M) | 853.9M | 410.5M | 851.1M |
| Income Tax Expense | (21.7M) | 88.9M | 142.4M | 89.4M | 164.6M |
| Bottom Line | |||||
| Net Income | 337.2M | (530.2M) | 711.5M | 321.1M | 686.5M |
| Earnings from Cont. Ops | 337.2M | (530.2M) | 711.5M | 321.1M | 686.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 337.2M | (530.2M) | 711.5M | 321.1M | 686.5M |
| Per Share | |||||
| Basic EPS | $0.50 | ($0.78) | $1.05 | $0.48 | $1.02 |
| Diluted EPS | $0.50 | ($0.78) | $1.04 | $0.47 | $1.01 |
| Revenue Per Share | $9.80 | $9.66 | $9.97 | $10.31 | $11.54 |
| Shares | |||||
| Basic Shares Outstanding | 677.1M | 678.0M | 680.3M | 675.6M | 650.9M |
| Diluted Shares Outstanding | 680.9M | 679.3M | 681.9M | 678.4M | 679.4M |
| Profitability Metrics | |||||
| EBITDA | 909.3M | 138.7M | 1.5B | 1.1B | 1.5B |
| D&A | 419.2M | 410.2M | 405.5M | 402.3M | 405.5M |
| EBIT | 490.1M | (271.5M) | 1.1B | 695.3M | 1.1B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026